Keyphrases
3′-untranslated Region (3′-UTR)
6%
Antagomir
40%
Brain Changes
6%
Cerebrospinal Fluid
6%
Clinical Recovery
6%
Clinical Subtypes
6%
Cognitive Assessment
6%
Cognitive Function
6%
Cognitive Impairment
26%
Experimental Ischemic Stroke
6%
FDA-approved Drugs
6%
Focal Ischemic Stroke
6%
Heterogeneous Disorder
6%
Hippocampal LTP
6%
Hippocampus
20%
Hippocampus-dependent Learning
6%
Hippocampus-dependent Memory
6%
Ischemic Stroke
6%
Long-term Disability
6%
MicroRNA
6%
Mild Cases
6%
Mild Stroke
6%
Mini-Mental State Examination
6%
MiR-15a
60%
MiR-20a
66%
Motor Recovery
6%
Motor-sensory
6%
Neurogenesis
13%
Neuropathology
6%
Older Persons
6%
Older Stroke Patients
6%
Pathophysiology
6%
Post-stroke Cognitive Impairment
100%
Preventive Effect
6%
Quality of Life
6%
Sensory Deficit
6%
Spatial Regulation
6%
Stroke Impairments
6%
Stroke Model
6%
Stroke Survivors
6%
Tempo-spatial Variation
6%
Transient MCAO
40%
Transient Middle Cerebral Artery Occlusion (tMCAO)
26%
Treatment Delay
6%
VEGF Expression
26%
Young Stroke Patients
6%
Neuroscience
Antagomir
24%
Brain Ischemia
12%
Cerebrovascular Accident
100%
Cognitive Disorders
100%
Hippocampus
16%
microRNA 15a
8%
microRNA 20a
40%
Middle Cerebral Artery
16%
Neurogenesis
8%
Vascular Endothelial Growth Factor
28%
Pharmacology, Toxicology and Pharmaceutical Science
Antagomir
24%
Brain Ischemia
12%
Cerebrovascular Accident
100%
Cognitive Defect
100%
microRNA 15a
8%
microRNA 20a
40%
Middle Cerebral Artery Occlusion
16%
Vasculotropin
28%